Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine Versus Probiotic as Adjuvant Therapy for Preterm Neonates With Bronchopulmonary Dysplasia
NCT05682807Phase 3Unknown
- Sponsor
- Tanta University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of caffeine in bronchopulmonary dysplasia (BPD), sponsored by Tanta University. Status: unknown.
02
Drugs
caffeine
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT05682807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682807.